Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. (Q30939083)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

0 references

Robert Graham G Russell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Frieder Bauss

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

English

0 references

publication date

26 March 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

Osteoporosis International

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

423-433

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

29 December 2019

cites work

1 reference

12 December 2020

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study

1 reference

12 December 2020

The relationship between three-dimensional connectivity and the elastic properties of trabecular bone

1 reference

12 December 2020

Structural requirements for bisphosphonate actions in vitro

1 reference

12 December 2020

Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis

1 reference

12 December 2020

The long-term effect of ovariectomy on the quality and quantity of cortical bone in the young cynomolgus monkey: a comparison of density fractionation and histomorphometric techniques

1 reference

12 December 2020

Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies

1 reference

12 December 2020

How often is medication taken as prescribed? A novel assessment technique

1 reference

12 December 2020

Editorial: Single daily dose of antidepressants

1 reference

12 December 2020

Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

1 reference

12 December 2020

The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat

1 reference

12 December 2020

Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study

1 reference

12 December 2020

Dosing regimens and main adverse events of bisphosphonates

1 reference

12 December 2020

Basic biomechanical measurements of bone: a tutorial

1 reference

12 December 2020

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

1 reference

12 December 2020

Epidemiology and outcomes of osteoporotic fractures

1 reference

12 December 2020

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

1 reference

12 December 2020

Intermittent and Continuous Administration of the Bisphosphonate Ibandronate in Ovariohysterectomized Beagle Dogs: Effects on Bone Morphometry and Mineral Properties

1 reference

12 December 2020

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

1 reference

12 December 2020

Effects of the bisphosphonate tiludronate on bone resorption, calcium balance, and bone mineral density

1 reference

12 December 2020

Bisphosphonates: pharmacology, mechanisms of action and clinical uses

1 reference

12 December 2020

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

1 reference

12 December 2020

Remodeling and the repair of fatigue damage

1 reference

12 December 2020

Treatment with ibandronate preserves bone in experimental tumour-induced bone loss

1 reference

12 December 2020

A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs

1 reference

12 December 2020

Preclinical pharmacology of alendronate

1 reference

12 December 2020

Pathogenesis of bone fragility in women and men.

1 reference

12 December 2020

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

1 reference

12 December 2020

The socioeconomic burden of fractures: today and in the 21st century

1 reference

12 December 2020

Bisphosphonates: mechanisms of action

1 reference

12 December 2020

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

1 reference

12 December 2020

Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation

1 reference

12 December 2020

Disuse bone loss in hindquarter suspended rats: partial weightbearing, exercise and ibandronate treatment as countermeasures

1 reference

12 December 2020

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis

1 reference

12 December 2020

Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.

1 reference

12 December 2020

The bone "quality" problem

1 reference

12 December 2020

Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats.

1 reference

12 December 2020

The ovariectomized rat model of postmenopausal bone loss

1 reference

12 December 2020

Characteristics of an ovariectomized osteopenic rat model

1 reference

12 December 2020

Treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Measuring compliance with inhaled medication in asthma

1 reference

12 December 2020

Inhibition of bone resorption by the bisphosphonate BM 21.0955 is not associated with an alteration of the renal handling of calcium in rats infused with parathyroid hormone-related protein

1 reference

12 December 2020

Overview of patient compliance with medication dosing: a literature review

1 reference

12 December 2020

Bisphosphonates: from the laboratory to the clinic and back again

1 reference

12 December 2020

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

1 reference

12 December 2020

Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis)

1 reference

12 December 2020

The crippling consequences of fractures and their impact on quality of life

1 reference

12 December 2020

On the rat model of human osteopenias and osteoporoses

1 reference

12 December 2020

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate

1 reference

12 December 2020

Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats

1 reference

12 December 2020

Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines

1 reference

12 December 2020

Pharmacokinetics of Clodronate after Single Intravenous, Intramuscular and Subcutaneous Injections in Rats

1 reference

12 December 2020

A one year follow-up study of the distribution of 14C-clodronate in mice and rats

1 reference

12 December 2020

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats

1 reference

12 December 2020

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats

1 reference

12 December 2020

Effects of long-term infusion of physiologic doses of 1-34 PTH on bone

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

1 reference

12 December 2020

Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals

1 reference

12 December 2020

Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S00198-004-1612-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15205712%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference